-
EP3423089
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3423089
| EP3423089 - ANTIBODIES TO TIGIT [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 03.04.2021 Database last updated on 21.12.2024 | |
| Former | Request for examination was made Status updated on 07.12.2018 | ||
| Former | The international publication has been made Status updated on 08.09.2017 | Most recent event Tooltip | 26.11.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states JN Biosciences, LLC 320 Logue Avenue Mountain View, CA 94043 / US | For all designated states Abmuno Therapeutics LLC 914 Channing Way Berkeley, CA 94710 / US | [2023/41] |
| Former [2019/02] | For all designated states JN Biosciences, LLC 320 Logue Avenue Mountain View, CA 94043 / US | ||
| For all designated states Abmuno Therapeutics LLC 914 Channing Way Berkeley, CA 94710 / US | Inventor(s) | 01 /
TSO, J., Yun 320 Logue Avenue Mountain View, CA 94043 / US | 02 /
TSURUSHITA, Naoya 320 Logue Avenue Mountain View, CA 94043 / US | 03 /
DURAMAD, Omar 914 Channing Way Berkeley, CA 94710 / US | [2019/02] | Representative(s) | Schnappauf, Georg ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [N/P] |
| Former [2019/02] | HGF Limited Saviour House 9 St. Saviourgate York YO1 8NQ / GB | Application number, filing date | 17760920.3 | 03.03.2017 | [2019/02] | WO2017US20719 | Priority number, date | US201662304045P | 04.03.2016 Original published format: US 201662304045 P | US201662413025P | 26.10.2016 Original published format: US 201662413025 P | [2019/02] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017152088 | Date: | 08.09.2017 | Language: | EN | [2017/36] | Type: | A1 Application with search report | No.: | EP3423089 | Date: | 09.01.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.09.2017 takes the place of the publication of the European patent application. | [2019/02] | Search report(s) | International search report - published on: | US | 08.09.2017 | (Supplementary) European search report - dispatched on: | EP | 25.09.2019 | Classification | IPC: | A61K39/00, A61K39/395, A61P37/02, C07K16/28, A61K39/08, A61K39/085, A61K39/39 | [2019/43] | CPC: |
A61K39/08 (EP,IL,KR,US);
A61K39/39541 (IL,US);
C07K16/2803 (EP,CN,IL,KR,US);
A61K39/085 (EP,IL,KR,US);
A61K39/39 (EP,IL,KR,US);
A61K39/3955 (IL,US);
A61P31/00 (EP,IL);
A61P31/04 (EP,IL);
A61P31/10 (EP,IL);
A61P31/12 (EP,IL);
A61P31/14 (EP,IL);
A61P31/16 (EP,IL);
A61P31/18 (EP,IL);
A61P31/20 (EP,IL);
A61P31/22 (EP,IL);
A61P33/02 (EP,IL);
A61P35/00 (EP,IL,KR);
A61P35/02 (EP,IL);
A61P37/02 (EP,IL);
A61P37/04 (EP,IL);
A61P43/00 (EP,IL);
C07K16/2809 (IL,US);
C07K16/2827 (EP,IL,US);
C07K16/2878 (IL,US);
C07K16/2896 (IL,US);
C07K16/3061 (IL,US);
A61K2039/507 (EP,IL,KR,US);
A61K2039/545 (EP,IL,KR,US);
A61K2121/00 (IL,US);
C07K2317/24 (EP,CN,IL,KR,US);
C07K2317/30 (IL,US);
C07K2317/33 (IL,US);
C07K2317/34 (EP,IL,KR,US);
C07K2317/56 (CN);
C07K2317/565 (CN);
C07K2317/70 (IL,US);
C07K2317/732 (EP,IL,US);
C07K2317/734 (EP,IL,US);
C07K2317/76 (EP,IL,KR,US);
C07K2317/90 (IL,US);
C07K2317/92 (EP,IL,KR,US);
C07K2317/94 (IL,US);
Y02A50/30 (EP,US)
(-)
|
| Former IPC [2019/02] | A61K39/00, A61K39/395, A61P37/02, C07K16/28 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/02] | Title | German: | ANTI-TIGIT-ANTIKÖRPER | [2019/02] | English: | ANTIBODIES TO TIGIT | [2019/02] | French: | ANTICORPS ANTI-TIGIT | [2019/02] | Entry into regional phase | 03.10.2018 | National basic fee paid | 03.10.2018 | Search fee paid | 03.10.2018 | Designation fee(s) paid | 03.10.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 03.10.2018 | Examination requested [2019/02] | 22.04.2020 | Amendment by applicant (claims and/or description) | 06.04.2021 | Despatch of a communication from the examining division (Time limit: M04) | 06.08.2021 | Reply to a communication from the examining division | 06.11.2023 | Despatch of a communication from the examining division (Time limit: M06) | 03.05.2024 | Reply to a communication from the examining division | 25.11.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 13.03.2019 | Renewal fee patent year 03 | 12.03.2020 | Renewal fee patent year 04 | 12.03.2021 | Renewal fee patent year 05 | 02.03.2022 | Renewal fee patent year 06 | 12.01.2023 | Renewal fee patent year 07 | 03.01.2024 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO2016028656 (MERCK SHARP & DOHME [US], et al); | International search | [A]US2011150903 (BAURIN NICOLAS [FR], et al); | [A]WO2012078793 (UNIV TEXAS [US], et al); | [Y]WO2016011264 (GENENTECH INC [US], et al); | [A]WO2016028656 (MERCK SHARP & DOHME [US], et al); | by applicant | US4634664 | US4634666 | WO9110741 | WO9117271 | WO9201047 | WO9220791 | WO9312227 | US5225539 | US5530101 | US5545806 | US5565332 | US5569825 | US5585089 | US5625126 | US5624821 | US5633425 | US5661016 | US5733743 | US5770429 | US5789650 | US5814318 | US5834597 | US5837242 | US5859205 | US5858657 | US5871907 | US5874299 | US5877397 | US5877218 | US6407213 | US6624821 | US6881557 | WO2016028656 |